Migliaccio & Rathod LLP is currently investigating weight-loss clinics and med-spas for potentially deceptive practices involving compounded semaglutide. Many consumers report receiving versions of the medication that may not contain semaglutide at all, or may include unverified or unsafe ingredients, despite being advertised as equivalent to brand-name drugs like Ozempic®.
Concerns About Drug Purity, Label Accuracy, and Safety
On February 28, 2025, the FBI and Internet Crime Complaint Center (IC3) issued a public warning that certain compounded “semaglutide” products sold at med-spas or pharmacies may lack active ingredients or contain impurities, leading to serious health issues including gastrointestinal distress and cardiovascular complications.
In April and May 2025, the FDA ended its enforcement discretion for compounded semaglutide, effectively tightening regulations. Despite this, compounded GLP-1 products continue to raise safety and labeling concerns.
Why This Matters for Consumers
Consumers who received compounded semaglutide injections may have been misled about the drug’s composition, safety, and effectiveness. Misrepresentation of medication content is a serious public health concern, especially when individuals are relying on these injections for chronic conditions like obesity or type 2 diabetes.
Did You Receive Compounded Semaglutide at a Clinic or Med-Spa?
If so, we want to hear from you. Please complete the questionnaire below. For more information or to submit documentation, contact us at [email protected] or call (202) 470-3520.